# Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients

> **NCT05222555** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Incyte Corporation** · enrollment: 53 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Tafasitamab
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT05222555
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-19
- **Primary completion:** 2024-07-17
- **Final completion:** 2027-11-30
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05222555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05222555, "Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05222555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*